Evidence map›Paper›PMID 28938401›Full record

ArticleThe Journal of clinical endocrinology and metabolism2017

N-Glycomic Profiling of Pheochromocytomas and Paragangliomas Separates Metastatic and Nonmetastatic Disease.

Helena Leijon, Tuomas Kaprio, Annamari Heiskanen, Tero Satomaa, Jukka O Hiltunen, Markku M Miettinen, Johanna Arola, Caj Haglund

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of clinical endocrinology and metabolism, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Helena LeijonDepartment of Pathology, University of Helsinki and HUSLAB, Helsinki University Hospital, FIN-00014 University of Helsinki, Helsinki, Finland.
Tuomas KaprioDepartment of Surgery, Päijät-Häme Central Hospital, 15850 Lahti, Finland.
Annamari HeiskanenGlykos Finland Ltd., 00790 Helsinki, Finland.
Tero SatomaaGlykos Finland Ltd., 00790 Helsinki, Finland.
Jukka O HiltunenGlykos Finland Ltd., 00790 Helsinki, Finland.
Markku M MiettinenLaboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.
Johanna ArolaDepartment of Pathology, University of Helsinki and HUSLAB, Helsinki University Hospital, FIN-00014 University of Helsinki, Helsinki, Finland.
Caj HaglundTranslational Cancer Biology, Research Programs Unit, University of Helsinki, FIN-00014 University of Helsinki, Helsinki, Finland.
Glykos (Finland) · FIUniversity of Helsinki · FIHelsinki University Hospital · FINational Cancer Institute · USPäijät-Hämeen Keskussairaala · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Context: No effective methods for separating primary pheochromocytomas and paragangliomas with metastatic potential are currently available. The identification of specific asparagine-linked glycan (N-glycan) structures, which are associated with metastasized pheochromocytomas and paragangliomas, may serve as a diagnostic tool. Objective: To identify differences in N-glycomic profiles of primary metastasized and nonmetastasized pheochromocytomas and paragangliomas. Setting: This study was conducted at Helsinki University Hospital, University of Helsinki, and Glykos Finland Ltd. and included 16 pheochromocytomas and paragangliomas: 8 primary metastasized pheochromocytomas or paragangliomas and 8 nonmetastasized tumors. Methods: N-glycan structures were analyzed with matrix-assisted laser desorption-ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) profiling of formalin-fixed, paraffin-embedded tissue samples. Main Outcome Measure: N-glycan profile of tumor tissue. Results: Four groups of neutral N-glycan signals were more abundant in metastasized tumors than in nonmetastasized tumors: complex-type N-glycan signals of cancer-associated terminal N-acetylglucosamine, multifucosylated glycans (complex fucosylation), hybrid-type N-glycans, and fucosylated pauci-mannose-type N-glycans. Three groups of acidic N-glycans were more abundant in metastasized tumors: multifucosylated glycans, acid ester-modified (sulfated or phosphorylated) glycans, and hybrid-type/monoantennary N-glycans. Fucosylation and complex fucosylation were significantly more abundant in metastasized paragangliomas and pheochromocytomas than in nonmetastasized tumors for individual tests but were over the false positivity critical rate, when adjusted for multiplicity testing. Conclusions: MALDI-TOF MS profiling of primary pheochromocytomas and paragangliomas can identify diseases with metastatic potential based on their different N-glycan profiles. Thus, malignancy-linked N-glycan structures may serve as potential diagnostic tools for pheochromocytomas and paragangliomas.

Indexed as

GlycomicsAdrenal Gland NeoplasmsAdultAgedDiagnosis, DifferentialFemaleGlycosylationHumansMaleMiddle AgedNeoplasm MetastasisNeoplasm StagingParagangliomaPheochromocytomaPolysaccharidesSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationPolysaccharides

Identifiers

PMID28938401
PMCPMC6283447
OpenAlexW2749895211

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.